Evolus Inc Stock Performance
| EOLS Stock | USD 13.04 0.41 3.25% |
The firm shows a Beta (market volatility) of 1.05, which means a somewhat significant risk relative to the market. Evolus returns are very sensitive to returns on the market. As the market goes up or down, Evolus is expected to follow. At this point, Evolus Inc has a negative expected return of -0.24%. Please make sure to confirm Evolus' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Evolus Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Evolus Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (1.46) | Five Day Return 7.35 | Year To Date Return 28.63 | Ten Year Return 11.74 | All Time Return 11.74 |
1 | Disposition of 5631 shares by Yamagishi-dressler Tomoko of Evolus at 15.85 subject to Rule 16b-3 | 08/30/2024 |
2 | Acquisition by Farrell Peter C of 11789 shares of Evolus at 10.25 subject to Rule 16b-3 | 09/04/2024 |
3 | Does Evolus Have A Healthy Balance Sheet | 10/22/2024 |
4 | Evolus Rewards Patient Loyalty Program Surpasses 1 Million Enrolled Consumers | 10/29/2024 |
5 | Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation | 10/31/2024 |
6 | Evolus Reports Third Quarter 2024 Results | 11/06/2024 |
7 | Evolus Posts Quarterly Earnings Results | 11/08/2024 |
8 | Evolus Inc Shares Gap Down to 12.58 on Nov 12 | 11/12/2024 |
9 | Stonepine Capital Management Increases Stake in Kiora Pharmaceuticals | 11/14/2024 |
10 | Analysis of TANG CAPITAL MANAGEMENT LLCs Recent Transaction in Reneo Pharmaceuticals Inc | 11/15/2024 |
11 | Stonepine Capital Management, LLC Increases Stake in OptiNose Inc | 11/21/2024 |
| Begin Period Cash Flow | 53.9 M |
Evolus |
Evolus Relative Risk vs. Return Landscape
If you would invest 1,581 in Evolus Inc on August 24, 2024 and sell it today you would lose (277.00) from holding Evolus Inc or give up 17.52% of portfolio value over 90 days. Evolus Inc is currently does not generate positive expected returns and assumes 3.3577% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Evolus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evolus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evolus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evolus Inc, and traders can use it to determine the average amount a Evolus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0724
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EOLS |
Estimated Market Risk
| 3.36 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Evolus is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evolus by adding Evolus to a well-diversified portfolio.
Evolus Fundamentals Growth
Evolus Stock prices reflect investors' perceptions of the future prospects and financial health of Evolus, and Evolus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evolus Stock performance.
| Return On Equity | -8.62 | ||||
| Return On Asset | -0.0993 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 844.59 M | ||||
| Shares Outstanding | 63.32 M | ||||
| Price To Earning | (5.55) X | ||||
| Price To Book | 135.78 X | ||||
| Price To Sales | 3.33 X | ||||
| Revenue | 202.09 M | ||||
| Gross Profit | 92.73 M | ||||
| EBITDA | (41.81 M) | ||||
| Net Income | (61.69 M) | ||||
| Cash And Equivalents | 84.48 M | ||||
| Cash Per Share | 1.51 X | ||||
| Total Debt | 126.55 M | ||||
| Debt To Equity | 1.59 % | ||||
| Current Ratio | 2.60 X | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (34.01 M) | ||||
| Earnings Per Share | (0.91) X | ||||
| Market Capitalization | 825.71 M | ||||
| Total Asset | 189 M | ||||
| Retained Earnings | (558.98 M) | ||||
| Working Capital | 64.13 M | ||||
| Current Asset | 27.24 M | ||||
| Current Liabilities | 76.8 M | ||||
About Evolus Performance
Assessing Evolus' fundamental ratios provides investors with valuable insights into Evolus' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Evolus is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 65.21 | 123.60 | |
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.33) | (0.34) | |
| Return On Equity | 2.98 | 3.13 |
Things to note about Evolus Inc performance evaluation
Checking the ongoing alerts about Evolus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evolus Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evolus Inc generated a negative expected return over the last 90 days | |
| Evolus Inc has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 202.09 M. Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 92.73 M. | |
| Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Over 80.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Stonepine Capital Management, LLC Increases Stake in OptiNose Inc |
- Analyzing Evolus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evolus' stock is overvalued or undervalued compared to its peers.
- Examining Evolus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evolus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evolus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evolus' stock. These opinions can provide insight into Evolus' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.